logo
Democrats sue over efforts to defund Planned Parenthood

Democrats sue over efforts to defund Planned Parenthood

Yahoo2 days ago
SACRAMENTO, California — Attorney General Rob Bonta and 22 other Democratic attorneys general and governors are suing the Trump administration over a bid to strip federal funds from Planned Parenthood clinics.
'We need to just call it what it is: punishment for Planned Parenthood's constitutionally protected advocacy for abortion,' Bonta said at a press conference Tuesday morning. 'The hypocrisy is really hard to ignore: a party that claims to be defenders of free speech only seem to care about it when it aligns with their own agenda.'
Congressional Republicans have wanted to cut funding to Planned Parenthood since Trump's first term. If they're successful, about 200 of the 600 clinics the nonprofit operates around the country could close, with over half of them in California.
'California is the most impacted state in the country,' said Jodi Hicks, CEO of Planned Parenthood Affiliates of California. 'It's important to have a California lens on this.'
Bonta, the other attorneys general, and the governor of Pennsylvania argue in their filing that the Republican mega-spending and policy bill Trump signed in early July violates the First Amendment by targeting Planned Parenthood's national umbrella organization for its advocacy. They also allege it violates the Constitution's spending clause by being too vague and illegally singles out Planned Parenthood for punishment without due process.
While the spending bill doesn't mention Planned Parenthood by name, it set funding criteria that targets the organization directly. The law bars Medicaid funds from going to reproductive health clinics that provide abortions and are part of national networks that received over $800,000 in Medicaid funding. Bonta said it isn't clear if any other providers would fall under the law, but at least one organization in Maine has also filed a suit.
Federal funds already cannot be used for abortion, but Planned Parenthood clinics rely heavily on Medicaid funding to cover other services, with as much as 50 percent of its patients nationally enrolled in the government program. In California, eight in ten patients are covered by Medicaid.
'The federal government is once again playing politics with our health care system, with devastating consequences,' New York Attorney General Letitia James said in a statement. 'This administration's shameful and illegal targeting of Planned Parenthood will make it harder for millions of people to get the health care they need.'
Bonta's lawsuit is separate from one filed by Planned Parenthood clinics in Massachusetts and Utah along with Planned Parenthood Federation of America, the umbrella organization that oversees state affiliates which run the clinics.
In that case, U.S. District Judge Indira Talwani on Monday ruled that her preliminary decision to block the legislation's funding cut would remain in place. In siding with Planned Parenthood's arguments, Talwani wrote that Congress was trying to illegally punish clinics for the political work of the broader Planned Parenthood organization. Planned Parenthood, she concluded, was the ''easily ascertainable' target of the law when the legislation was passed.'
Talwani also found that apart from the abortions the clinics perform, patients who rely on them for other services such as cancer screenings and testing for sexually transmitted diseases would be harmed if Medicaid funding was cut off.
In the week leading up to Talwani's decision, California's clinics were briefly defunded and five clinics closed down, Planned Parenthood Mar Monte announced.
'That lawsuit is just one strategy to fight back, and the reality is that an attack this severe requires a multi pronged response with both short and long term strategies,' Hicks said. 'These attacks are not going away, and this administration has certainly shown their colors.'
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kamala Harris' latest Stephen Colbert flop shows exactly what's wrong with both of them
Kamala Harris' latest Stephen Colbert flop shows exactly what's wrong with both of them

New York Post

time6 minutes ago

  • New York Post

Kamala Harris' latest Stephen Colbert flop shows exactly what's wrong with both of them

Kamala Harris' visit Thursday to Stephen Colbert's 'Late Show' was a fine reminder of why both of them are failures. Mind you, this marked Harris' eighth Late Show appearance — one more illustration of the futility of doing the same thing over and over and somehow expecting different results. What made her think this would help promote her new book? Advertisement The marquee moment was her inability to say who's leading the Democratic Party just now — which was actually simple honesty, since neither Dems nor Republicans have clear leaders these days unless it's a sitting president. But she couldn't explain that simple truth, nor did Colbert show any sign of getting it as he pushed for an answer. Her incoherence was part of another classic Kam performance, full of word salads and non-answers. Advertisement So why did Colbert even bring her on a supposed comedy show? Because he's followed most of the late-night crew down the 'we need to promote liberal politics' toilet, of course — hosting 176 Dem politicians and one Republican since 2022, and hewing one side of the aisle every minute in between. That formula earned him cancellation and may well take out all his peers. It's another puzzle of modern life that so much of the entertainment industry somehow forgot that sanctimoniousness (political or otherwise) is the enemy of humor.

The Supreme Court just dropped a hint about its next big Voting Rights Act case
The Supreme Court just dropped a hint about its next big Voting Rights Act case

Politico

time7 minutes ago

  • Politico

The Supreme Court just dropped a hint about its next big Voting Rights Act case

The order came in a case challenging Louisiana's congressional map, which contains two majority-Black districts out of the state's six House seats. The court heard arguments in the case in March and had been expected to rule by June. But on June 27, the justices punted the case into their next term and ordered that it be reargued. Now, Friday's order loosely sketches the terrain on which the justices want further arguments: the claim that the longstanding practice of drawing majority-minority districts under the Voting Rights Acts may be unconstitutional because of its focus on race in drawing district lines. The voters challenging Louisiana's map had already advanced that constitutional claim in the case, but the justices' call for further briefing on the issue suggests they want to consider the claim more fully. Section 2 of the Voting Rights Act, a landmark law passed during the civil rights era, generally prohibits race-based discrimination in voting laws and practices. In redistricting, the law is used to protect against racial gerrymandering that would unfairly dilute the voting power of racial and ethnic minority voters. States across the country routinely seek to comply with Section 2 by drawing congressional districts where minority voters can elect their chosen candidates. Louisiana's previous map contained only one majority-Black district, even though Black residents make up about a third of the state's population. After a court struck down that map for likely violating the Voting Rights Act because it diluted the power of Black voters, the state's Republican-controlled legislature drew the new map with two majority-Black districts. A group of voters — who self-identified as non-Black — challenged the new map. That's the case now before the Supreme Court. A ruling overturning the current map could result in Republicans picking up an additional congressional seat in Louisiana. The state's two majority-Black districts are both represented by Democrats, while the other four districts are represented by Republicans.

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say
Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say

CBS News

time7 minutes ago

  • CBS News

Pfizer CEO attending $25 million fundraiser at Trump's golf club after president demands drug price cuts, sources say

Pfizer CEO Albert Bourla is among those expected at a fundraiser President Trump is attending Friday at his golf club in Bedminster, New Jersey, sources told CBS News. The fundraiser for the pro-Trump super political action committee MAGA Inc. aims to raise about $25 million, one of the sources said. One day prior to the event, Mr. Trump sent letters to pharmaceutical companies, including Pfizer, demanding they lower U.S. drug prices to more evenly match what other countries pay. The White House's letters to 17 drug companies, including AstraZeneca, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson and Sanofi, asked for commitments within 60 days to sell drugs for Medicaid patients and all new drugs at "most favored nation" rates. The president posted images of the letters to Truth Social. Mr. Trump signed an executive order in May telling federal officials to draw up "most favored nation" regulations unless pharmaceutical companies made progress toward cutting prices. This week's letters — which were addressed to Bourla and the other CEOs — accused the drugmakers of promising "more of the same" since then. The president said Friday he's "gone to war with the drug companies and, frankly, other countries" on the drug price issue. "I think we're going to be very successful fairly soon. We'll have drug prices coming down by 500, 600 800 even 1,200 percent," Mr. Trump said in an interview with Newsmax on Friday afternoon. The high cost of prescription drugs has vexed both parties for decades. Proposals to tie drug prices for U.S. patients to the typically much-lower rates charged in other developed countries have floated around for years, but the idea has faced some legal pushback. Meanwhile, drugmakers argue price caps could discourage innovation by making it harder to pay for research and development for new drugs. The industry also argues that Americans tend to have access to more groundbreaking drugs than residents of foreign countries with stricter price regulations — and says high drug prices are just one part of a broader trend of higher healthcare spending in the U.S. Bourla has engaged with Mr. Trump in the past. Pfizer was one of the drugmakers that was picked to rapidly develop COVID-19 vaccines in the first Trump administration's "Operation Warp Speed." And two weeks before Mr. Trump's second inauguration, Bourla and other Pfizer executives traveled to Mar-A-Lago for meetings, the Financial Times has previously reported. CBS News has reached out to Pfizer and the White House for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store